In ovarian cancer, miR-181a promotes the Wnt/β-catenin signaling pathway by targeting and inhibiting SFRP4, a Wnt signaling pathway inhibitor, hence augmenting ovarian cancer stem cell (OCSC) traits and generating resistance to platinum-based chemotherapy. Here, SFRP4 is linked to ovarian carcinoma.